Hints and tips:
Showing results for v. Teva Pharmaceuticals USA, Inc.
Related Special Reports
...It exited its position in generic drugs maker Teva and sold more than 70 per cent of its remaining shares in AbbVie and Bristol-Myers Squibb....
...That might justify a steeper EV-to-forward ebitda multiple than the seven times commanded by quoted generics companies Teva and Viatris. The unit might fetch at least $15bn, according to Bernstein....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Its case against Endo, Teva, and Allergan is currently being tried in state court. The settlement payments to New York will begin this summer and continue over the next 17 years....
...James added that the pharmaceutical company’s heavy marketing of opioids was partially motivated by quotas for sales staff....
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...The company already held stakes in the drugmakers Biogen, Johnson & Johnson and Teva Pharmaceuticals and DaVita, a kidney dialysis company. Mr Buffett did not respond to a request for comment....
...“I feel very strongly that we should get as many shots in arms as possible, right away,” Mr Gottlieb told USA Today last week. “The reality is that one dose is partially protective....
...The Pfizer vaccine, which needs to be kept at under minus 70 degrees Celsius during transit, is transported from Ben Gurion airport to logistics centres run by a subsidiary of Teva Pharmaceuticals, a global...
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...To boost supplies of antimalarials, generics manufacturers Teva and Novartis’ Sandoz have pledged to donate millions of doses to US hospitals....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...Teva, Mylan and others in the lawsuits have denied wrongdoing....
...Teva Pharmaceuticals, the only remaining manufacturer, fell 1.6 per cent to $7.38, after losing 3.5 per cent during the trading day....
...Endo International, a pharmaceutical company, fell 9 per cent to $2.65; Teva, the Israeli drugmaker, lost 4.6 per cent to $7.08; and McKesson, another distributor, fell 3 per cent to $142.55 in late-morning...
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...There are civil suits against much larger companies including Johnson & Johnson and Teva, as well as distributors and pharmacies....
...Inc — in other words offering a dire signal on the outlook”....
...The state argued that J&J’s previous ownership of Noramco and Tasmanian Alkaloids, units which produced the active pharmaceutical ingredient in opioids and supplied to Purdue and Teva, made it a “drug kingpin...
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...Earlier this year Purdue Pharma settled the Oklahoma case for $270m without admitting liability, and Israeli drugmaker Teva Pharmaceuticals settled for $85m....
...Pfizer has reached a deal to spin off its Upjohn unit and combine it with generics drugmaker Mylan to create an off-patent pharmaceutical group with an enterprise valuation of about $50bn....
...In particular, WBA pointed to a 2.3 per cent year-on-year rise in sales at its main Retail Pharmacy USA division, with a rise in pharmacy sales offsetting declining retail sales....
...Plus, the FT’s pharmaceutical and biotech reporter, Hannah Kuchler, explains why a lawsuit backed by 44 US states alleges that some generic drugmakers, including Teva and Pfizer, have been fixing prices...
International Edition